Immune checkpoint blockade (ICB) using anti-programmed cell death 1 (anti-PD-1) antibodies, either as monotherapy, or in combination with anti-CTL-associated protein 4 (anti-CTLA-4) antibodies, is currently one of the most effective standard therapies for late-stage melanoma (1–5). This evidence concerns the gene PDCD1 and melanoma.